Can-Fite BioPharma Ltd. (CANF)
Can-Fite BioPharma Ltd. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Can-Fite BioPharma Ltd. (CANF) is a Biotechnology company based in IL with a market capitalization of $1.8M. Revenue declined 39.4% year-over-year and free cash flow was negative at -$9M. This page tracks CANF's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
IL · 5 employees · IPO Nov 6, 2012
Valuation
Valuation & price
$3.45as of May 26, 2026· -75.7% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
0.32
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$1.8M
Market cap
-39.4%
Revenue growth (YoY)
94.1%
Gross margin
-$9M
Free cash flow (USD)
-$8.5M
Net debt
Net cash position
-88.6%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 6-K filed Jul 6, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 6-K filingJul 20, 2026Filing
Positive Study Data Presentation
- 6-K filingJul 14, 2026Filing
Patent Allowance Secured
- Quarterly reportJul 6, 2026Filing
Interim Results (6-K)
- 6-K filingJul 1, 2026Filing
Clinical Study Results
- 6-K filingJun 26, 2026Filing
Patent Allowance Secured
- 6-K filingJun 22, 2026Filing
Scientific Article Publication
- 6-K filingJun 17, 2026Filing
Conference Participation Announcement
- 6-K filingJun 4, 2026Filing
Annual General Meeting Results
- 6-K filingJun 2, 2026Filing
Positive Clinical Observation
- 6-K filingMay 28, 2026Filing
Annual General Meeting Update
Questions
Frequently asked questions
What is Can-Fite BioPharma Ltd.'s market cap?
Can-Fite BioPharma Ltd. (CANF) has a market capitalization of $1.8M.
What is CANF's P/E ratio?
A meaningful P/E ratio is not available for CANF — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is CANF's price-to-book (P/B) ratio?
CANF trades at 0.32 times book value per share.
Are insiders buying CANF stock?
SEC Form 4 filings show no open-market insider buys at Can-Fite BioPharma Ltd. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.